K
46.14
-0.88 (-1.87%)
| Previous Close | 47.02 |
| Open | 47.02 |
| Volume | 140,553 |
| Avg. Volume (3M) | 622,966 |
| Market Cap | 3,531,342,080 |
| Price / Earnings (TTM) | 61.52 |
| Price / Earnings (Forward) | 57.47 |
| Price / Sales | 5.48 |
| Price / Book | 6.34 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2026 |
| Profit Margin | -3.52% |
| Operating Margin (TTM) | 9.63% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 72.50% |
| Total Debt/Equity (MRQ) | 2.17% |
| Current Ratio (MRQ) | 3.66 |
| Operating Cash Flow (TTM) | 44.03 M |
| Levered Free Cash Flow (TTM) | 25.15 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -3.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Kiniksa Pharmaceuticals Interna | Bullish | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | 4.0 |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 3.80% |
| % Held by Institutions | 97.31% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fairmount Funds Management Llc | 31 Dec 2025 | 1,319,688 |
| Pictet Asset Management Holding Sa | 31 Dec 2025 | 787,520 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 62.00 (Canaccord Genuity, 34.37%) | Buy |
| Median | 53.00 (14.87%) | |
| Low | 53.00 (Wedbush, 14.87%) | Buy |
| 53.00 (Wells Fargo, 14.87%) | Buy | |
| Average | 56.00 (21.37%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 44.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 25 Feb 2026 | 53.00 (14.87%) | Buy | 42.76 |
| 13 Jan 2026 | 50.00 (8.37%) | Buy | 38.60 | |
| Wells Fargo | 25 Feb 2026 | 53.00 (14.87%) | Buy | 42.76 |
| Canaccord Genuity | 19 Feb 2026 | 62.00 (34.37%) | Buy | 47.17 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| RAGOSA MARK | - | 46.74 | -36,722 | -1,716,386 |
| Aggregate Net Quantity | -36,722 | |||
| Aggregate Net Value ($) | -1,716,386 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 46.74 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RAGOSA MARK | Officer | 09 Mar 2026 | Automatic sell (-) | 36,722 | 46.74 | 1,716,386 |
| RAGOSA MARK | Officer | 09 Mar 2026 | Option execute | 36,722 | - | - |
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Kiniksa Pharmaceuticals Provides Corporate Update |
| 07 Jan 2026 | Announcement | Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |